IMEIK: Subsidiary obtains Minoxidil topical solution "Drug Registration Certificate"
I'm LongbridgeAI, I can summarize articles.IMEIK's wholly-owned subsidiary, Beijing Nuobote Biotechnology Co., Ltd., recently obtained the "Drug Registration Certificate" for Minoxidil topical solution approved by the National Medical Products Administration. This medication is available in two specifications: 2% and 5%, primarily used for the treatment of androgenetic alopecia and alopecia areata. Minoxidil is a peripheral vasodilator that can stimulate hair growth with long-term use
According to the Zhitong Finance APP, IMEIK (300896.SZ) announced that its wholly-owned subsidiary Beijing Nuobote Biotechnology Co., Ltd. ("Nuobote") has received the drug registration certificates approved and issued by the National Medical Products Administration for minoxidil lotion with specifications of 2% and 5%.
It is reported that minoxidil lotion is a non-prescription dermatological medication. The 2% specification is used for the treatment of male pattern hair loss and alopecia areata; the 5% specification is limited to male use for the treatment of male pattern hair loss and alopecia areata. Minoxidil is a peripheral vasodilator that, when used topically over a long period, can stimulate hair growth in patients with male pattern hair loss and alopecia areata